HCV Treatment
Coverage of the 2017 Conference on Retroviruses and Opportunistic Infections
- Details
- Category: HIV Treatment
- Published on Sunday, 16 April 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2017 Conference on Retroviruses and Opportunistic infections (CROI 2017), February 13-16, 2017, in Seattle.
Full coverage listing by topic
4/16/17
EASL 2017: International Liver Congress Starts This Week in Amsterdam
- Details
- Category: HBV Treatment
- Published on Thursday, 13 April 2017 00:00
- Written by Liz Highleyman
The European Association for the Study of the Liver (EASL) International Liver Congress (ILC 2016) will take place April 19-23 at the RAI Centre in Amsterdam. The congress is one of the major annual scientific meetings covering hepatitis B and C and its complications, as well as other liver diseases. HIVandHepatitis.com and our partners at aidsmap.com will be providing on-site coverage of meeting highlights.
CROI 2017: Glecaprevir/ Pibrentasvir for HCV Can Be Safely Administered with Common Antiretrovirals
- Details
- Category: Experimental HCV Drugs
- Published on Saturday, 18 February 2017 00:00
- Written by Liz Highleyman
AbbVie's investigational glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact with or require dose adjustment when taken with commonly used antiretroviral regimens, offering a new option for HIV/HCV coinfected people, according to a study presented at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.
FDA Approves Harvoni and Sovaldi for Adolescents with Hepatitis C
- Details
- Category: Approved HCV Drugs
- Published on Saturday, 08 April 2017 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) on April 7 approved the first direct-acting antivirals for the treatment of chronic hepatitis C virus (HCV) infection in adolescents age 12 to 17 years. Sofosbuvir/ledipasvir (Harvoni) is now indicated for adolescents with HCV genotypes 1, 4, 5, or 6, while sofosbuvir (Sovaldi) plus ribavirin is approved for those with genotypes 2 or 3.
Gilead and AbbVie Seek FDA Approval of Pangenotypic Hepatitis C Treatments
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 27 December 2016 00:00
- Written by Liz Highleyman
Gilead Sciences and AbbVie both announced this month that they have applied for U.S. Food and Drug Administration approval of new all-oral ribavirin-free combination regimens to treat all genotypes of hepatitis C virus (HCV). Gilead's sofosbuvir/velpatasvir/ voxilaprevir and AbbVie's glecaprevir/pibrentasvir have demonstrated high cure rates in Phase 3 clinical trials.
Web Design and Development by